T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$2B |
| 2 |
Sea Limited
SE
|
+$1.34B |
| 3 |
Morgan Stanley
MS
|
+$1.23B |
| 4 |
Incyte
INCY
|
+$1.05B |
| 5 |
Ross Stores
ROST
|
+$968M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.05B |
| 2 |
VMW
VMware, Inc
VMW
|
+$1.5B |
| 3 |
Visa
V
|
+$1.16B |
| 4 |
JPMorgan Chase
JPM
|
+$1.13B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.01% |
| 2 | Healthcare | 17.6% |
| 3 | Consumer Discretionary | 14.37% |
| 4 | Financials | 11.89% |
| 5 | Communication Services | 10.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACIA
2076
DELISTED
Acacia Communications Inc
ACIA
| $460K | ﹤0.01% |
6,843
+215
| +3% | +$14.6K |
|
2077
SITE Centers
SITC
$158M
| $459K | ﹤0.01% |
72,691
-938
| -1% | -$4.59K |
|
|
LAND
2078
Gladstone Land Corp
LAND
$358M
| $456K | ﹤0.01% |
28,766
-4,494
| -14% | -$62.9K |
|
|
SRNE
2079
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $456K | ﹤0.01% |
72,546
-3,643
| -5% | -$13.9K |
|
2080
BancFirst
BANF
$3.89B
| $452K | ﹤0.01% |
11,151
+43
| +0.4% | +$1.58K |
|
2081
Boise Cascade
BCC
$2.94B
| $452K | ﹤0.01% |
12,015
+129
| +1% | +$4.04K |
|
2082
Banner Corp
BANR
$2.5B
| $451K | ﹤0.01% |
11,875
+42
| +0.4% | +$1.49K |
|
2083
Community Trust Bancorp
CTBI
$1.44B
| $451K | ﹤0.01% |
13,774
-1,627
| -11% | -$52.3K |
|
|
SHYF
2084
DELISTED
The Shyft Group
SHYF
| $450K | ﹤0.01% |
26,695
-20,102
| -43% | -$304K |
|
|
VNE
2085
DELISTED
Veoneer, Inc.
VNE
| $449K | ﹤0.01% |
42,006
-10,812
| -20% | -$106K |
|
|
CNR
2086
Core Natural Resources Inc
CNR
$4.64B
| $445K | ﹤0.01% |
87,765
-10,999
| -11% | -$68.6K |
|
2087
Anavex Life Sciences
AVXL
$303M
| $444K | ﹤0.01% |
90,162
-24,714
| -22% | -$93.4K |
|
|
UNIT
2088
Uniti Group
UNIT
$2.38B
| $444K | ﹤0.01% |
47,531
-36,131
| -43% | -$271K |
|
|
CHNG
2089
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $443K | ﹤0.01% |
39,582
+28,734
| +265% | +$323K |
|
|
CLVS
2090
DELISTED
Clovis Oncology, Inc.
CLVS
| $441K | ﹤0.01% |
65,267
-12,075
| -16% | -$91.4K |
|
|
AERI
2091
DELISTED
Aerie Pharmaceuticals
AERI
| $441K | ﹤0.01% |
29,852
+2,988
| +11% | +$44.2K |
|
|
SPTN
2092
DELISTED
SpartanNash
SPTN
| $440K | ﹤0.01% |
20,691
+175
| +0.9% | +$3.14K |
|
2093
Arrow Financial
AROW
$723M
| $438K | ﹤0.01% |
16,576
+2,550
| +18% | +$62.4K |
|
2094
Forrester Research
FORR
$224M
| $435K | ﹤0.01% |
13,588
+47
| +0.3% | +$1.49K |
|
|
ZYNE
2095
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
| $435K | ﹤0.01% |
129,000
+17,952
| +16% | +$84.9K |
|
2096
Nu Skin
NUS
$236M
| $434K | ﹤0.01% |
11,341
-15,207
| -57% | -$489K |
|
2097
Willdan Group
WLDN
$1.29B
| $434K | ﹤0.01% |
17,335
+3
| +0% | +$69 |
|
2098
Koppers
KOP
$874M
| $433K | ﹤0.01% |
22,981
+162
| +0.7% | +$2.46K |
|
2099
Trupanion
TRUP
$1.36B
| $433K | ﹤0.01% |
10,140
+484
| +5% | +$15.7K |
|
2100
Univest Financial
UVSP
$1.19B
| $432K | ﹤0.01% |
26,748
-7,796
| -23% | -$125K |
|
Similar funds
T. Rowe Price Associates's Q2 2020 Portfolio in Review
As of Q2 2020, T. Rowe Price Associates held 2,591 positions worth $795B, up 26% from $632B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
T. Rowe Price Associates's Q2 2020 filing shows 79 new, 1,096 increased, 1,255 reduced and 100 closed positions. Its largest new stake was Vroom Inc: 200,362 shares worth $797M. The largest sale was Boeing, an estimated $2.05B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2020 buy was Vroom Inc: 200,362 shares worth $797M.
- T. Rowe Price Associates added most to Microsoft in Q2 2020, an estimated $2B increase.
- T. Rowe Price Associates's biggest Q2 2020 reduction was Boeing, cutting an estimated $2.05B.
- T. Rowe Price Associates fully exited Raytheon Company in Q2 2020, selling an estimated $1.01B.
- T. Rowe Price Associates's ten largest holdings make up 25% of its $795B portfolio in Q2 2020.
- T. Rowe Price Associates opened 79 new positions and closed 100 in Q2 2020.
- T. Rowe Price Associates's portfolio value rose 26% quarter-over-quarter to $795B.
Based on T. Rowe Price Associates's 13F filing for Q2 2020, filed 14 Aug 2020.